Biogen is a major biotechnology company that develops treatments for neurological and rare diseases. Its lobbying focuses on health policies such as drug pricing, drug development, screening and diagnosis, and issues affecting Alzheimer’s disease and ALS; it also lobbies on tax reform, trade (including tariffs and intellectual property), and pharmacy matters. The company reports hiring DLA Piper and spent about $180,000 across recent filings.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
KARINA LYNCH
The latest disclosures for this client.
DLA PIPER LLP (US)
Q2DLA PIPER LLP (US)
Q1The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
DLA PIPER LLP (US)
MARGARET MARTIN
DLA PIPER LLP (US)
MICHAEL SORENSEN
DLA PIPER LLP (US)
RICHARD BURR
DLA PIPER LLP (US)
MAREN MCBRIDE
DLA PIPER LLP (US)
RACHEL PORTMAN
DLA PIPER LLP (US)
DLA PIPER LLP (US)
Q4DLA PIPER LLP (US)
Q3DLA PIPER LLP (US)
Q2DLA PIPER LLP (US)
RR